┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0117
  SLUG ................ /gsk-paroxetine-publication-restrictions
  STATUS .............. ACTIVE
  FILED ............... 2026-06-15 07:48 UTC
  LAST ANNOTATED ...... 2026-06-15 07:48 UTC
  CLAIMS ON FILE ...... 9
  MEAN TAG CONFIDENCE . 0.79
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

GSK Contractual Restrictions on Paroxetine Research Publication

SUMMARY

This investigation concerns whether GlaxoSmithKline (GSK) contractually restricted Martin Keller's ability to publish findings unfavorable to the antidepressant paroxetine (marketed as Paxil/Seroxat), and the specific terms of any such agreements. The broader context includes allegations that GSK concealed negative trial results for paroxetine, particularly in relation to 'Study 329,' which investigated its efficacy and harms in adolescents. Critics allege that GSK executives internally acknowledged 'commercially unacceptable' results for Study 329 and sought to disguise its failure, leading to a misleading published article. A lawsuit filed by New York state's attorney general, Eliot Spitzer, accused GSK of 'repeated and persistent fraud' for allegedly concealing negative trial results.

While there are documented claims of publication bias in antidepressant literature, where positive findings are more likely to be published, and specific allegations against GSK for distorting or failing to publish negative results from Study 329, direct evidence detailing contractual clauses restricting an individual researcher like Martin Keller from publishing unfavorable findings is not explicitly present in the provided sources. The focus of the available information is on corporate suppression of data rather than individual contractual terms with specific researchers.

STRONGEST CASE FOR

GSK likely implemented contractual clauses or institutional pressures that effectively restricted researchers, including Martin Keller, from publishing negative findings regarding paroxetine. The company's alleged actions in the case of Study 329, where internal emails reportedly acknowledged 'commercially unacceptable' results and a subsequent publication was criticized for distorting data, suggest a pattern of suppressing unfavorable information. It is plausible that direct or indirect contractual terms, or the implicit power dynamics between a pharmaceutical company and its contracted researchers, would have made it difficult for an individual to release data that contradicted the company's marketing objectives, regardless of scientific integrity.

STRONGEST CASE AGAINST

There is no direct evidence provided to suggest that GSK specifically contractually restricted Martin Keller's right to publish unfavorable findings. While allegations of publication bias and corporate suppression of negative trial results for paroxetine exist, these do not automatically equate to individual researcher contracts with explicit clauses preventing publication. The focus of the public discourse and legal actions appears to be on GSK's corporate handling and publication of study results, such as Study 329, rather than specific, named researchers being gagged by individual contracts. The absence of such contractual details in available public records suggests that any such restrictions may not have been explicitly documented or were not the primary mechanism of alleged data suppression.

CLAIMS

  1. VERIFIEDCONF 0.90

    GSK (then SmithKline Beecham) funded Study 329, an eight-week, double-blind, randomized clinical trial for paroxetine conducted between 1994 and 1997.

    — attributed to: Wikipedia, Study 329 article

    • https://en.wikipedia.org/wiki/Study_329
  2. CORROBORATEDCONF 0.80

    Study 329 failed to show any meaningful benefit for paroxetine.

    — attributed to: Public Health Policy Journal and Reddit users

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
    • https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/
  3. SINGLE-SOURCECONF 0.70

    Internal company emails admitted that Study 329 results were 'commercially unacceptable' and that disclosure would 'undermine the profile of paroxetine.'

    — attributed to: Public Health Policy Journal

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud_is_finally_under_review/
  4. SINGLE-SOURCECONF 0.70

    GSK was accused of setting out to disguise the failure of Study 329 as a success.

    — attributed to: Public Health Policy Journal

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud_is_finally_under_review/
  5. CORROBORATEDCONF 0.80

    The original publication of Study 329 in the Journal of the American Academy of Psychiatry and the Child was misleading.

    — attributed to: BMJ and Reddit users

    • https://www.bmj.com/bmj/section-pdf/749788?path=%2Fbmj%2F347%2F7933%2FFeature.full.pdf
    • https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/
  6. VERIFIEDCONF 0.90

    GlaxoSmithKline faced a lawsuit by New York state's attorney general, Eliot Spitzer, for alleged concealment of negative trial results for paroxetine, charging the company with 'repeated and persistent fraud.'

    — attributed to: PMC NCBI

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC421770/
  7. CORROBORATEDCONF 0.90

    There is a general problem of publication bias in antidepressant literature, where positive findings are far more likely to be published than null or negative findings.

    — attributed to: Cambridge University Press and Loyola University Chicago Law eCommons

    • https://www.cambridge.org/core/product/identifier/9781009391733%23bp16/type/book_part
    • https://lawecommons.luc.edu/cgi/viewcontent.cgi?article=1858&context=facpubs
  8. CORROBORATEDCONF 0.80

    Most negative results from drug trials are not published at all, or are published with evidence distortions.

    — attributed to: Loyola University Chicago Law eCommons

    • https://lawecommons.luc.edu/cgi/viewcontent.cgi?article=1858&context=facpubs
  9. SINGLE-SOURCECONF 0.60

    Paxil (paroxetine) is ineffective and harmful when taken by adolescents, contrary to GSK's publication.

    — attributed to: Reddit users citing a review of GSK's original data

    • https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/

TIMELINE

  • 1994-1997Acute phase of Study 329 conducted, funded by SmithKline Beecham. [src]
  • 2001Original publication of Study 329 in the Journal of the American Academy of Psychiatry and the Child.
  • 2002Over two million prescriptions for paroxetine written for children or adolescents in the US. [src]
  • 2004New York state's attorney general, Eliot Spitzer, files a civil suit against GSK for alleged concealment of negative trial results. [src]

ENTITIES

  • ORG GlaxoSmithKline (GSK) — Pharmaceutical company accused of concealing trial results
  • PERSON Martin Keller — Researcher whose publication rights are under investigation
  • ORG Paroxetine (Paxil/Seroxat) — Antidepressant drug under scrutiny for trial data suppression
  • EVENT Study 329 — Clinical trial for paroxetine in adolescents
  • PERSON Eliot Spitzer — Former New York Attorney General who filed suit against GSK
  • ORG SmithKline Beecham — Predecessor to GlaxoSmithKline

OPEN QUESTIONS — PENDING LEADS

  • Are there any publicly available contractual agreements between GSK and individual researchers involved in paroxetine trials, specifically Martin Keller, that detail publication rights?
  • Do any declassified legal documents or court filings from the Eliot Spitzer lawsuit against GSK contain specific clauses or discussions about individual researcher contracts and publication restrictions?
  • Have any whistleblowers or former GSK employees provided testimony or documentation regarding policies or clauses that restricted researchers' ability to publish unfavorable findings?
  • What specific role did Martin Keller play in Study 329, and are there any personal statements or communications from him regarding publication pressures or restrictions?
  • Are there any academic or journalistic investigations that have specifically focused on contractual clauses between pharmaceutical companies and researchers regarding the suppression of negative trial results, beyond general publication bias?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://lawecommons.luc.edu/cgi/viewcontent.cgi?article=1858&context=facpubs
    negative results were accu- rately published, most of the negative results were not published at all, and 11 were published with evidence distortions to ...
  2. [REDDIT] https://www.reddit.com/r/UnresolvedMysteries/comments/8ewi0v/district_attorney_confirms_earonsgsk_is_indeed/
    District Attorney confirms EAR/ONS/GSK is indeed the Visalia Ransacker in the Press Conference which is ongoing right now.
  3. [WEB] https://documents1.worldbank.org/curated/en/099427406022240207/txt/IDU035ccddd30ce3b0465f0a97d0f2ce539a2f7f.txt
    If you wish to re-use a component of the work, it is your responsibility to determine whether permission is needed for that re-use and to obtain permission ...
  4. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC421770/ [archived]
    The British pharmaceutical giant GlaxoSmithKline (GSK) is facing a major lawsuit in the United States over alleged concealment of negative trial results involving its antidepressant paroxetine (marketed there as Paxil and in Britain as Seroxat). The civil suit, filed by New York …
  5. [WEB] https://www.cambridge.org/core/product/identifier/9781009391733%23bp16/type/book_part
    13 Mar 2025 · the literature on antidepressants is riddled with publication bias: Positive findings are far more likely to be published than are null and ...
  6. [WEB] https://www.bmj.com/bmj/section-pdf/749788?path=%2Fbmj%2F347%2F7933%2FFeature.full.pdf
    Witty, with a final plea to help correct the scientific record. "Your corporation has so far failed to take responsibility for a published report that has harmed young patients who wer prescribed paroxetine on the basis of this misleading article. As the CEO of GSK, you have the …
  7. [WEB] https://researchonline.lshtm.ac.uk/id/eprint/4677333/1/Kendrick-etal-2025-Internet-and-telephone-intervention.pdf [archived]
    Adverse events are likely to be few, and usually not serious, so trying to help patients come off long-term antidepressants when appropriate is a relatively ...
  8. [WEB] https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
    The first, known as Study 329, failed to show any meaningful benefit. In one internal email, company executives admitted the results were "commercially unacceptable" and that disclosure of the poor efficacy data would "undermine the profile of paroxetine." Rather than accept the …
  9. [REDDIT] https://www.reddit.com/r/biotech/comments/17vhjdu/what_severance_package_did_you_get_from_big/ [archived]
    What severance package did you get from big pharma layoffs? If you don't mind to share. . Share Add a Comment Sort by: Best Open comment sort options Top New Controversial Old Q&A syntheticassault •
  10. [REDDIT] https://www.reddit.com/r/biotech/comments/17cm1uu/gsk_layoffs/ [archived]
    I have worked for GSK for a long time in the past. This is pretty normal most Pharma have a reorg every three years and major restructuring when every a new Head of R&D is appointed, which is linked to company performance and economic outlook.
  11. [REDDIT] https://www.reddit.com/r/biotech/comments/19dwqi6/opinion_on_gsk/ [archived]
    News about any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use. | Or we can talk about career advice. Whatever.
  12. [WEB] https://en.wikipedia.org/wiki/Study_329 [archived]
    Over two million prescriptions for paroxetine were written for children or adolescents in the US in 2002. [29] Funded by SmithKline Beecham, the acute phase of study 329 was an eight-week, double-blind, randomized clinical trial conducted in 12 university or hospital psychiatric …
  13. [REDDIT] https://www.reddit.com/r/Anxiety/comments/vvmv2d/paxil_paroxetine_success_story_and_the_withdrawal/ [archived]
    I quit Paroxetine in Jan end 2022 First withdrawal was tension headaches in Feb 2022 that lasted for 2 weeks March 2022 : tension headaches reoccurrence along with acid reflux unexplained April 2022 : acid reflux reoccurrence along with pharyngitis and throat issues Soft palate r…
  14. [REDDIT] https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/ [archived]
    Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. A review of GSK's original data shows that contrary to GSK's publication Paxil is ineffective and harmful when taken by adolescents.
  15. [REDDIT] https://www.reddit.com/r/academia/comments/6nqvyb/i_just_found_out_that_someone_else_did_the_same/ [archived]
    Okay so i'm currently in a humanities undergrad summer research program and i'm about 60% of the way through the program. Just about an hour ago I was on google scholar looking for some sources for my paper and I came across a chapter of a thesis published two months ago that's l…
  16. [REDDIT] https://www.reddit.com/r/biotech/comments/1bjit46/how_long_does_gsk_usually_take_to_respond_to_a/ [archived]
    Pfizer a couple years ago for example got back to me in a few days for an interview. On the flip side a CDMO in Northern Ireland only offered me an interview 2 months after I applied. According to workday it's under "recruiter review". So in your experience how long does GSK usua…

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015) — SHARES-ACTOR (INCOMING)GLAXOSMITHKLINE FINANCIAL…GSK Contractual Restrictions on Paroxetine Research PublicationGSK CONTRACTUAL RESTRICTION…THIS FILESHARES-EVENTSHARES-ACTOR